|
|
Volumn 7, Issue 10, 2006, Pages 807-808
|
|
Appraisal of bevacizumab and cetuximab for treatment of metastatic colorectal cancer in the UK.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
BEVACIZUMAB;
CETUXIMAB;
MONOCLONAL ANTIBODY;
ARTICLE;
CLINICAL TRIAL;
COLORECTAL TUMOR;
CONTROLLED CLINICAL TRIAL;
DRUG APPROVAL;
DRUG LEGISLATION;
ECONOMICS;
HUMAN;
LEGAL ASPECT;
METASTASIS;
ORGANIZATION AND MANAGEMENT;
PATHOLOGY;
RANDOMIZED CONTROLLED TRIAL;
TREATMENT OUTCOME;
UNITED KINGDOM;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC AGENTS;
COLORECTAL NEOPLASMS;
DRUG APPROVAL;
GREAT BRITAIN;
HUMANS;
LEGISLATION, DRUG;
NEOPLASM METASTASIS;
RANDOMIZED CONTROLLED TRIALS;
TREATMENT OUTCOME;
|
|
EID: 33750951966
PISSN: 14702045
EISSN: None
Source Type: Journal
DOI: 10.1016/S1470-2045(06)70898-1 Document Type: Article |
|
Times cited : (6)
|
|
References (0)
|
